BR112015022624A2 - regime de dose, e, método para tratamento de aterosclerose - Google Patents

regime de dose, e, método para tratamento de aterosclerose

Info

Publication number
BR112015022624A2
BR112015022624A2 BR112015022624A BR112015022624A BR112015022624A2 BR 112015022624 A2 BR112015022624 A2 BR 112015022624A2 BR 112015022624 A BR112015022624 A BR 112015022624A BR 112015022624 A BR112015022624 A BR 112015022624A BR 112015022624 A2 BR112015022624 A2 BR 112015022624A2
Authority
BR
Brazil
Prior art keywords
apo
treatment cycle
treating atherosclerosis
dose regimen
effective amount
Prior art date
Application number
BR112015022624A
Other languages
English (en)
Inventor
Goldberg Dennis
M Anantharamaiah G
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of BR112015022624A2 publication Critical patent/BR112015022624A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

1 / 1 resumo “regime de dose, e, mã‰todo para tratamento de aterosclerose” essa invenã§ã£o fornece regimes de dosagens e mã©todos para tratamento de aterosclerose com uma quantidade eficaz de um mimã©tico de apo e para fornecer efeitos terapãªuticos sustentados mesmo apã³s a retirada do tratamento. os regimes de dosagens e mã©todos envolvem um ciclo de tratamento seguido por uma fase de repouso em que o paciente ã© administrado com uma quantidade eficaz de um mimã©tico de apo e durante o ciclo de tratamento e sem mimã©tico de apo e durante a fase de repouso. o ciclo de tratamento e a fase de repouso podem variar.
BR112015022624A 2013-03-14 2014-03-14 regime de dose, e, método para tratamento de aterosclerose BR112015022624A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US201361834992P 2013-06-14 2013-06-14
PCT/US2014/027719 WO2014152776A1 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof

Publications (1)

Publication Number Publication Date
BR112015022624A2 true BR112015022624A2 (pt) 2017-10-31

Family

ID=51581312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022624A BR112015022624A2 (pt) 2013-03-14 2014-03-14 regime de dose, e, método para tratamento de aterosclerose

Country Status (12)

Country Link
US (1) US20160002315A1 (pt)
EP (1) EP2996706B1 (pt)
JP (2) JP6570511B2 (pt)
AU (2) AU2014239186B2 (pt)
BR (1) BR112015022624A2 (pt)
CA (1) CA2903869A1 (pt)
DK (1) DK2996706T3 (pt)
ES (1) ES2753381T3 (pt)
IL (1) IL240787B (pt)
MX (1) MX2015012818A (pt)
NZ (1) NZ713291A (pt)
WO (1) WO2014152776A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074923B (zh) 2014-07-31 2021-08-03 Uab研究基金会 Apoe模拟肽及对清除血浆胆固醇的较高效力
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
HRP20230992T1 (hr) * 2016-02-17 2023-12-08 Regeneron Pharmaceuticals, Inc. Postupci za liječenje ili sprečavanje ateroskleroze davanjem inhibitora angptl3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8557767B2 (en) * 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US20130005645A1 (en) * 2010-01-06 2013-01-03 Vitek Michael P Apoe peptide dimers and uses thereof
CN107074923B (zh) * 2014-07-31 2021-08-03 Uab研究基金会 Apoe模拟肽及对清除血浆胆固醇的较高效力

Also Published As

Publication number Publication date
JP6570511B2 (ja) 2019-09-04
AU2014239186A1 (en) 2015-10-08
AU2017203911B2 (en) 2019-03-07
NZ713291A (en) 2017-04-28
MX2015012818A (es) 2016-05-12
JP2019089834A (ja) 2019-06-13
IL240787B (en) 2019-07-31
WO2014152776A1 (en) 2014-09-25
CA2903869A1 (en) 2014-09-25
EP2996706A1 (en) 2016-03-23
DK2996706T3 (da) 2019-10-21
AU2014239186B2 (en) 2017-04-20
AU2017203911A1 (en) 2017-06-29
JP2016515137A (ja) 2016-05-26
EP2996706B1 (en) 2019-07-31
JP6772317B2 (ja) 2020-10-21
EP2996706A4 (en) 2017-01-18
US20160002315A1 (en) 2016-01-07
IL240787A0 (en) 2015-10-29
ES2753381T3 (es) 2020-04-08

Similar Documents

Publication Publication Date Title
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CO6300949A2 (es) Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada
BR112015023725A2 (pt) composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
BR112018014850A2 (pt) dispositivo de injeção usável
BR112015018418A2 (pt) métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
PE20151374A1 (es) Regimen de dosificacion de un sedante
BR112014009785A8 (pt) método para tratar ou reduzir efp
BR112017021383A2 (pt) regime de dosagem para doses omitidas de ésteres de paliperidona injetáveis de longa ação
BR112017000556A2 (pt) terapia de combinação para câncer
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112015022624A2 (pt) regime de dose, e, método para tratamento de aterosclerose
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
BR112014011223A8 (pt) Método de tratar uma doença proliferativa
BR112015022513A2 (pt) produto e método para tratamento de diarreia
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
BR112018069174A2 (pt) tratamento de prurido urêmico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: UAB RESEARCH FOUNDATION (US) , LIPIMETIX DEVELOPME

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.